J Clin Psychiatry

1. ANDRADE C
   The Position of Clozapine in Patients With Treatment-Resistant Schizophrenia: Reply to Mattes.
   J Clin Psychiatry. 2026;87:25lr16256a.
   

   >> Share

   
   

   
   J Clin Psychopharmacol

2. HSIEH MH, Huang HH, Huang SC, Hou PY, et al
   Nonabsorption of Paliperidone Palmitate Suspension Two Months After Administration in a Patient With Schizophrenia and Keloid: A Case Report.
   J Clin Psychopharmacol. 2026 Jan 28. doi: 10.1097/JCP.0000000000002130.
   

   >> Share

   
   
3. KEMPINGER LM, Wiss FM, Lampert ML, Sociu A, et al
   P-Glycoprotein-Related Interactions With Paliperidone May Result in Subtherapeutic Drug Levels and Clinical Exacerbation of Schizophrenia: A Case Report.
   J Clin Psychopharmacol. 2026 Jan 26. doi: 10.1097/JCP.0000000000002131.
   

   >> Share

   
   
4. ZHAND N, Joober R, Labelle A, Attwood D, et al
   Efficacy of Low-Dose Adjunctive Methylphenidate Extended-Release on Cognition and Functioning in Individuals With Schizophrenia: A Randomized Open-Label Trial.
   J Clin Psychopharmacol. 2026 Jan 26. doi: 10.1097/JCP.0000000000002132.
   

   >> Share

   
   

   
   J Psychiatry Neurosci

5. FORTIN-LATOUR E, Stip E
   Persistent genital arousal symptoms in a young woman with recurring brief psychoses: a clinical dilemma in antipsychotic choice.
   J Psychiatry Neurosci. 2026;51:1-2.
   

   >> Share

   
   

   
   Psychiatry Res

6. CHANALIA S, Grover S, Chakrabarti S
   A comparative study of medication adherence in schizophrenia patients receiving clozapine and other antipsychotics.
   Psychiatry Res. 2025;358:116879.
   

   >> Share

   
   
7. STABELL LA, Johnsen E, Kroken R, Loberg EM, et al
   Levels of and changes in psychosis symptoms and clinical insight: Exploring the impact of differential antipsychotic mechanisms.
   Psychiatry Res. 2026;358:116948.
   

   >> Share

   
   
8. MUSTONEN A, Niemela S, Denissoff A, Forti MD, et al
   Optimizing antipsychotic dosing for relapse prevention in cannabis-induced psychosis: A nationwide cohort study.
   Psychiatry Res. 2026;358:116966.
   

   >> Share

   
   
9. ASENJO-LOBOS C, Arancibia M, Cortes-Jofre M, Huang T, et al
   Comparative efficacy and safety of clozapine and olanzapine in schizophrenia and related disorders: An updated systematic review.
   Psychiatry Res. 2026;358:116956.
   

   >> Share

   
   

   
   Schizophr Res

10. SISMAN O, Onen S
    Corrigendum to "prevalence and multidimensional impact of sarcopenia in schizophrenia: Associations with oxidative stress, functioning, and symptom severity" [Schizophr. Res. volume 289, March 2026, pages-61-70].
    Schizophr Res. 2026 Jan 28:S0920-9964(26)00024.
    

    >> Share

    
    
11. CHEN BY, Lin JJ, Tseng HH, Huang CC, et al
    Small EVs miRNA profiles and their expressions in EVs-depleted plasma as an optimal combination panel for treatment-resistant schizophrenia.
    Schizophr Res. 2026;290:17-29.
    

    >> Share

    
    
12. FONSECA L, Ito LT, Ziebold C, Rohde LA, et al
    Executive function mediates the effects of genetic liability to schizophrenia on behavior and functioning in a community sample of children and adolescents.
    Schizophr Res. 2026;290:9-16.
    

    >> Share

    
    
13. MITTAL VA, Chang WC, Walker EF
    Negative symptoms across developmental stages in psychosis spectrum.
    Schizophr Res. 2026;289:100-105.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share